MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Berkeley Lights ROA Ratio 2011-2026 | BLI
Annual ROA Ratio Berkeley Lights
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.36 | -24.97 | -13.88 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.88 | -43.36 | -27.4 |
Quarterly ROA Ratio Berkeley Lights
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54.33 | -36.51 | -27.59 | -34.37 | -31.96 | -27.75 | -18.01 | -22.06 | -18.15 | -16.16 | -13.88 | -12.47 | -13.0 | -13.57 | -10.76 | -8.12 | -4.72 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.72 | -54.33 | -21.38 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Adagene
ADAG
|
-37.44 | $ 2.91 | 5.05 % | $ 164 M |  China |
 |
ANI Pharmaceuticals
ANIP
|
-1.44 | $ 82.0 | 3.13 % | $ 1.58 B | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.58 | -1.53 % | $ 16.2 M | USA |
 |
Beam Therapeutics
BEAM
|
-34.13 | $ 29.29 | 0.93 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
5.82 | $ 176.18 | 0.77 % | $ 25.7 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-34.19 | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
BioNTech SE
BNTX
|
65.02 | $ 116.77 | 0.53 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.26 | -3.55 % | $ 7.84 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 4.1 | -1.2 % | $ 8.92 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
-73.35 | $ 10.15 | -5.45 % | $ 668 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Cerus Corporation
CERS
|
-10.41 | $ 2.32 | -1.69 % | $ 428 M | USA |
 |
Aptose Biosciences
APTO
|
-251.11 | - | -45.71 % | $ 1.2 M | Canada |
 |
Coherus BioSciences
CHRS
|
-37.78 | $ 2.33 | 5.19 % | $ 219 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Brickell Biotech
BBI
|
-49.15 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 223.95 | 0.67 % | $ 5 B |  Danmark |
 |
Cellectis S.A.
CLLS
|
-32.74 | $ 3.99 | -1.72 % | $ 116 M | France |
 |
Athira Pharma
ATHA
|
-164.92 | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 9.66 | 1.9 % | $ 1.52 B | Britain |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.12 | $ 69.12 | 5.4 % | $ 9.25 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.25 | $ 24.58 | 1.57 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
-46.74 | $ 1.62 | -0.31 % | $ 77.2 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-104.83 | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-40.29 | - | -15.15 % | $ 60.3 M | Britain |
 |
DBV Technologies S.A.
DBVT
|
-173.5 | $ 22.96 | -3.41 % | $ 2.23 B | France |
 |
Amneal Pharmaceuticals
AMRX
|
-2.11 | $ 14.11 | 1.15 % | $ 4.36 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |